DALLAS, Texas , Sept 12, 2022 /PRNewswire/ — Neurolens, a company commercializing innovative solutions to optimize vision, today announced completion of a $67 million financing. The financing was led by MVM Companions, with additional participation through Falcon Vision/KKR, Marshall Wace , and existing investors including Bluestem Capital.

The particular investment will fuel continued product innovation and growth initiatives, further accelerating the adoption of Neurolens.

“While we have grown tenfold in the past three years, the particular unmet patient need remains massive, ” said Pierre Bertrand , Neurolens CEO. “Nearly 6 out of 10 Americans are reporting daily symptoms of Digital Vision Syndrome, and we are excited to continue bringing solutions in order to independent optometry to meet their needs. We are grateful to see both current and new investors embrace our mission to transform eyecare beyond visual acuity. ”

Dr. Eric Bednarski , Partner at MVM, commented “Neurolens offers a remarkable solution to address the widespread problems that patients experience due to DVS. We are usually pleased to partner with Neurolens to support its continued growth. inch Dr . Akhilesh Pathipati , Partner at MVM, added “The team at Neurolens has shown tremendous leadership plus dedication while innovating within a market poised for growth. We are thrilled to work with them to continue changing the lives of individuals. ” Drs. Bednarski and Pathipati joined the Neurolens Board associated with Directors as a part of this financing.

The investment follows two recent announcements signaling the unprecedented acceleration of Neurolens within the vision industry. In late August, Inc. revealed that Neurolens had been recognized as the 28 th fastest growing healthcare company on its annual Incorporation. 5000 list, a prestigious ranking of the fastest-growing private companies in America. Earlier in August, Neurolens released the results of the parallel arm study evaluating reading speed at baseline. The study revealed that after seven days associated with lens wear, the average improvement in reading speed with Neurolenses has been almost 70% higher than the improvement seen with other premium lens designs.

To learn more about Neurolens, please visit our website in https://www.neurolens.com .

About Neurolens

Neurolens commercializes breakthrough technology to improve vision care. With patented Contoured Prism technology, Neurolenses are the particular first plus only prescription lenses that will go past visual awareness to provide comfort  for the  majority of adults who complain of headaches, neck/shoulder pain and eyestrain when using digital devices, reading through or doing detail work .   The particular Neurolens Contoured Prism design helps the eyes function together comfortably, bringing the particular eyes into alignment in order to relieve painful symptoms. Technology from Neurolens is only available to Independent Eye Care Providers.

About MVM Partners

MVM has invested in high growth healthcare businesses since 1997. The firm has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, digital health, and other sectors of healthcare.

About Falcon Vision

Falcon Vision is an ophthalmology-focused platform supported by KKR. The platform invests in and manages a diversified portfolio of emerging assets across medical devices and biopharmaceuticals. Falcon Vision’s strategy is to tackle the need for capital, access to executive talent, and operational guidance in order to support advancement of revolutionary products with regard to under-managed ophthalmic diseases plus vision preservation. Falcon Eyesight collaborates with the team from Flying L Partners to identify and execute new opportunities.

Regarding Marshall Wace

Founded in 1997, Marshall Wace is a global alternative investment manager. Marshall Wace combines fundamental investing along with systematic and quantitative strategies utilizing proprietary systems plus processes.

Media Contact
Shannon Severino
[email protected]

SOURCE Neurolens

Leave a Reply

Your email address will not be published. Required fields are marked *